
    
      Subject participation for this study will be 2 years post-transplant. Subjects who enroll in
      this study will be asked to participate in a subsequent long-term follow up study that will
      monitor the safety and efficacy of the treatment they receive for an additional 13 years for
      a total of 15 years post-drug product infusion.
    
  